Anti-infective monoclonal antibody - Aridis Pharmaceuticals

Drug Profile

Anti-infective monoclonal antibody - Aridis Pharmaceuticals

Alternative Names: Aerucin

Latest Information Update: 20 Jan 2016

Price : $50

At a glance

  • Originator Kenta Biotech
  • Developer Aridis Pharmaceuticals
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis; Pneumonia

Most Recent Events

  • 07 Jan 2016 Adverse events data from a phase I trial in healthy volunteers released by Aridis Pharmaceuticals
  • 03 Nov 2015 Phase-I clinical trials in Cystic fibrosis in USA (Parenteral) prior to November 2015 (Aridis Pipeline, November 2015)
  • 13 Oct 2015 Aridis Pharmaceuticals receives SBIR grant from the National Institutes of Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top